Twist Bioscience Corporation Income (Loss) from Continuing Operations before Income Taxes, Domestic
Twist Bioscience Corporation (TWST) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$78.49 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-17.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2025-11-17
- Twist Bioscience Corporation income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$78.49M.
- Twist Bioscience Corporation income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$209.54M.
- Twist Bioscience Corporation income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$205.39M.
- Twist Bioscience Corporation income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$231.66M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-09-30 | -$78.49M 10-K · filed 2025-11-17 |
| 2024-09-30 | -$209.54M 10-K · filed 2025-11-17 |
| 2023-09-30 | -$205.39M 10-K · filed 2025-11-17 |
| 2022-09-30 | -$231.66M 10-K · filed 2024-11-18 |
| 2021-09-30 | -$149.53M 10-K · filed 2023-11-21 |
| 2020-09-30 | -$138.02M 10-K/A · filed 2023-06-05 |
| 2019-09-30 | -$107.85M 10-K · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |